Skip to main content
ZVRA
NASDAQ Life Sciences

Zevra Q2 Revenue Surges 53% to $39.7M, Beats Consensus; Cash Pile Grows to $260M After Debt Payoff

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$10.5
Mkt Cap
$622.482M
52W Low
$7.16
52W High
$15.035
52W Position info
47% above low
Off High info
30% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ZVRA sits 47% above its 52-week low of $7.16.

Summary

Zevra's Q2 revenue of $39.7M beat estimates by 17%, fueled by MIPLYFFA. The company is debt-free with $260M in cash, but faces a European regulatory hurdle for arimoclomol.


Key Events · Earnings and Guidance · ZVRA

  • Q2 Revenue Beats Consensus

    Revenue of $39.66M grew 53% YoY, exceeding the $33.88M consensus. MIPLYFFA contributed $30.2M and the global expanded access program added $9.0M.

  • Debt-Free Balance Sheet

    The $63.1M term loan was fully repaid in March 2026. Cash, equivalents, and investments totaled $260.2M at quarter-end, providing a multi-year runway.

  • European Regulatory Setback

    In July 2026, the CHMP adopted a negative opinion on the arimoclomol MAA. Zevra has requested a re-examination; a final decision is pending.

  • Celiprolol Phase 3 Enrollment Update

    The DiSCOVER trial for Vascular Ehlers-Danlos syndrome has enrolled 66 participants as of June 30, 2026. A Type C meeting with the FDA was held in Q1 2026 to discuss potential acceleration.


Analysis · ZVRA · Life Sciences

Accelerating commercial traction for Zevra's rare-disease drugs marks the second quarter. Revenue jumped 53% year-over-year to $39.7 million, handily beating the $33.9 million consensus, driven by MIPLYFFA sales and expanded access program reimbursements. The company is now debt-free after repaying its $63.1 million term loan in March, and its cash and investments stand at $260.2 million — a fortress balance sheet that removes near-term financing risk. A setback came with the negative CHMP opinion on the European marketing application for arimoclomol, though a re-examination has been requested. Meanwhile, the celiprolol Phase 3 trial continues to enroll, with 66 participants as of quarter-end. This report confirms Zevra's transition to a self-funding commercial-stage rare disease company with ample runway.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZVRA was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $622.5M. The 52-week trading range was $7.16 to $15.04. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZVRA - Latest Insights

ZVRA
Nov 13, 2026, 6:26 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.10
Real-time Price: $9.15 info
Change: -$0.955 (-9%) info
Market Cap: $544.17M info
ZVRA
Nov 03, 2026, 5:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.50
Real-time Price: $9.15 info
Change: -$1.36 (-13%) info
Market Cap: $544.17M info
ZVRA
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.26
Real-time Price: $9.15 info
Change: -$1.12 (-11%) info
Market Cap: $544.17M info
ZVRA
Aug 05, 2026, 5:10 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $10.60
Real-time Price: $9.15 info
Change: -$1.45 (-14%) info
Market Cap: $544.17M info
ZVRA
Jun 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.42
Real-time Price: $9.15 info
Change: -$3.28 (-26%) info
Market Cap: $544.17M info